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ALTERATIONS IN EXPRESSION OF THE MOTILITY-RELATED 
PROTEINS THYMOSIN (315 AND P120CAS IN HUMAN CANCER. 
Jason S. Gold, Rola A. D. Goussoub, and David L. Rimm. Department of 
Pathology, Yale University, School of Medicine, New Haven, Connecticut. 
Metastasis, the invasion of distant tissues, is a poor prognostic sign in 
cancer. Cell motility is involved in mediating metastasis. Thymosin (315 is a 5300 
Da protein known to function as an actin monomer binding protein. 
Overexpression of thymosin (315 has been shown to cause increased motility. 
P120cas is part of a complex of proteins that is critical for cell-cell adhesion, 
though the precise function of pl20cas is not known. The complex is also involved 
in motility, differentiation, and signal transduction. Given the functions of these 
two proteins, it is hypothesized that thymosin (315 expression should be increased 
and pl20cas expression should be decreased in the metastatic phenotype. Human 
cancers were assessed for alterations in these potential prognostic markers. The 
expression of thymosin (315 was examined in human breast cancer, and pl20cas 
was examined in human colorectal cancer. Surgical pathology slides were 
stained using standard immunohistochemical methods. Thymosin (315 
expression was found to be increased in malignant breast tissue compared with 
benign breast epithelium (p = 0.0002) . This change is found in intra-epithelial 
cancers as well as in metastatic and nonmetastatic infiltrating cancers. 
Expression of the adhesion-related protein pl20cas is decreased in colorectal 
cancer compared to benign epithelium. Decreased pl20cas expression correlates 
with advanced stage (p = 0.0470), nodal metastasis (p = 0.0426), and 
lymphovascular invasion (p = 0.0156). Decreased pl20cas expression is also 
associated with larger tumors (p = 0.0120). Loss of pl20cas furthermore 
corresponds with decreased survival (p = 0.0126) and decreased disease-free 
survival (p = 0.0313). 
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General Introduction 
1 
Cancer is not one disease but a spectrum of related diseases often 
with very different behaviors and implications. Nevertheless, cancer has 
historically been grouped together as one entity, and in fact, these diseases 
share some fundamental similarities in their pathology. When considered 
as a whole, cancer undeniably has an enormous impact on humankind. 
In this country, well over one million people will be diagnosed with 
cancer this year. Over half a million will die cancer-related deaths this 
year, making this the second leading cause of death next to heart disease. 
About one half of all Americans will develop a cancer in their lifetime. [1] 
An aging population and our ever increasing ability to detect new cases 
promises to increase the incidence of cancer even further. While it may be 
easy to quantitate the number of individuals affected or killed, the cost to 
society both financially and emotionally is harder to assess. Hopefully, 
medicine in the next century will be able to face this challenge with 
improved therapy. 
All cancers have at their heart the same underlying pathology. Cells 
derived from within the victim’s body grow uninhibited and can invade into 
surrounding tissues or implant at distant sites. The differentiation of the 
cancer defines the disease and separates it from other cancers. Thus a 
cancer that arises in and architecturally resembles the ducts in the 
pancreas cannot be considered synonymous with a cancer arising in and 
resembling the glands of the prostate. While the end results may be 
dramatically different, there are many similarities in the path that a cell 
must travel to give rise to any cancer. 
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Contemporary theory holds that every cancer derives from a single 
cell. This is called the clonal hypothesis. That cell must undergo a series 
of nonlethal genetic changes to become a full-blown carcinoma. In other 
words, a normal cell will suffer one insult and give rise to a slightly more 
nefarious clone of cells. One cell within this clone will theoretically suffer 
yet another change that will allow its progeny to become the dominant cells 
within the new growth until one of these cells is mutated into yet a more 
lethal clone. This is called clonal expansion. [2, 3] 
Much of this theory is old. Almost as long as pathologists have 
looked at cancer under the microscope, they have recognized that though 
cancers often resemble their tissue of origin, it is the cancers that grow in a 
seemingly unregulated pattern, very much unlike their native tissue, that 
behave badly. In addition, carcinomas in their earliest form — small, 
contained within the epithelial cell layer, or arising in an otherwise benign 
growth — are often relatively normal appearing indicating that the further 
advanced lesions have suffered more changes separating them from their 
host. [4] 
The idea that genetic changes are at the heart of the development of 
cancer from normal tissue is somewhat newer[5]. And only recently have 
the specific genetic events responsible for this metamorphosis begun to be 
appreciated. Much of this knowledge comes from colorectal cancer, which 
serves as the best model to study this process. As previously hypothesized 
in the multi-step theory, cells suffer a series of genetic changes that propel 
them through the development from a benign growth to a carcinoma. 
Even the earliest growth, which in the colorectal model is a small 
adenomatous polyp, is monoclonal in origin whereas the surrounding 
tissue is polyclonal [61. Polyps seem to preferentially arise from areas of 

3 
epithelial hyperproliferation indicating that the normal tissue is altered 
even before a polyp forms[7, 8]. Genetic changes seem to occur in two basic 
ways — genes that normally suppress tumor growth, tumor suppressor 
genes, are lost or altered such that they cannot function in that manner, 
while simultaneously genes that normally promote growth in a regulated 
fashion, proto-oncogenes, are altered such that they lose their regulation 
and promote uncontrolled growth. The mechanisms by which these 
changes can occur are multi-fold and include loss of chromosomes or 
pieces of chromosomes, chromosomal rearrangements, spontaneous 
mutations, and viral-mediated changes. Furthermore, these insults can be 
caused by various environmental factors or they can be inherited. [4] 
As a tumor progresses from a benign growth and becomes 
increasingly more uninhibited and develops histopathological features 
more suggestive of carcinoma, the number of genetic changes detected 
increases. While it appears that these changes may often occur in a 
preferred sequence, it is the accumulation of these changes and not the 
order in which they arise that determines the tumor’s biology. [3] 
If genetic changes are the basis for the development of a cancer from 
a normal cell, these alterations must mediate a number of functions found 
in the cancer but not in the normal tissue. For instance these changes 
must be able to promote the unregulated growth not only of the clonal 
portions of the tumor but also of the connective tissue elements as well — 
this often requires the proliferation of nonclonal cellular elements. Thus 
the ability of a tumor to recruit the formation of new vessels, angiogenesis, 
must be mediated by genetic changes. Genetic changes must also be 
responsible for the ability of a tumor to invade and travel through tissues, to 
gain access to the blood stream or lymphatics, as well as to attach to a new 
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site and thrive there. The ability of tumors to evade the body’s mechanisms 
of destroying cells with foreign elements must derive from genetic changes. 
The functions listed above are all complex and each involves multiple 
components. 
Thus while it is obvious now that in cancer there are genes altered 
and hence proteins directly changed in nature or expression, there must 
also be a whole host of changes in cellular organization and protein 
composition that are indirectly caused by insults the cell has suffered in its 
DNA. In other words the proteins altered at the DNA level must be involved 
in complex pathways that cause alterations in expression, localization, 
splicing and destruction of mRNA and proteins where the code is not 
directly affected at the DNA level. 
The examination of the totality of changes in human cancers can 
serve many functions. At the most fundamental level, associating the 
changes in cell structure with the related changes in function will allow 
science to gain a better understanding of the various molecular components 
of the cell and their functions in the normal state as well as in disease. The 
understanding of how cancer cells differ from normal cells could also 
conceivably provide targets for more rational cancer therapy. 
Careful documentation of the changes in neoplastic cells may allow 
for better diagnosis of cancer when pieces of tissue, single cells or maybe 
even just molecules are taken from a patient and examined. Thus this 
would hopefully allow for less invasive means to be used to make or rule out 
a diagnosis. Furthermore, in addition to making a diagnosis on a binary 
level — either malignant or benign — appreciation of the molecular basis of 
cancer may allow a better understanding of the behavior of various tumors 
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to be used for prognosis or for better subgrouping of patients for appropriate 
treatment. 

The Thymosin (315 Study 
6 
INTRODUCTION: 
Breast Cancer: 
One in eight women will develop breast cancer in her lifetime. While 
the incidence of this disease continues to gradually increase, mortality has 
begun to fall [ 1, 9]. Thus fewer women are dying from breast cancer, while 
more are living often comfortable and productive lives with the disease. 
Though early detection — provided by the increased use of mammography 
and the self-exam — combined with the wide acceptance of breast-sparing 
surgery have reduced the death and disfigurement from this disease, 
breast cancer still takes a significant toll. About 185,000 people will be 
diagnosed with breast cancer this year, and about 45,000 will die from 
breast cancer[ll. 
While there are many histological subtypes of breast cancer, ductal 
carcinoma is responsible for 80 percent of cases. The next most common 
variant, lobular carcinoma is responsible for another 10 percent. There are 
similarly many etiologies ascribed to breast cancer. As breast cancer is a 
hormonally associated tumor, many of the risk factors relating to a 
woman’s menstrual periods and pregnancy share a commonalty in that 
they all result in prolonged exposure of the breast to estrogen. [10] Family 
history is also notably a risk factor for breast cancer with about five to 10 
percent of all cases and 25 percent of cases diagnosed before age 30 
attributable to a familial syndrome such as the breast or breast-ovarian 
cancer syndromes caused by mutation of BRCA1 or BRCA2[11]. 

7 
The molecular basis of breast cancer is not nearly as well understood 
as it is for colorectal cancer (see below). Similarly, the multi-step 
hypothesis is not well established. There are many benign histological 
variations in breast tissue. For the most part, the clinical significance of 
these changes lies in their ability to mimic early breast cancer by 
presenting as a lump or a mammographic abnormality. However, some 
proliferative lesions seem to correlate with an increased risk of breast 
cancer especially when cellular atypia is found[12]. It is unclear whether 
breast cancer arises from areas of atypical hyperplasia directly, or 
alternatively if atypical hyperplasia and breast cancer both result from a 
common cause such as an inciting environmental agent or a hereditary 
predisposition. In the breast, cancer can be found lurking in the ducts or 
lobules as an in situ carcinoma. While this is generally thought of as a less 
advanced form of the disease, it is unclear whether breast cancer is able to 
proliferate only within the ducts and lobules before it acquires the ability to 
invade through the basement membrane and infiltrate into the 
parenchyma. 
As far as the oncogenes and tumor suppressor genes involved in 
breast cancer go, the gene known as erbB-2, HER-2, or neu is perhaps the 
most extensively studied. Interestingly, this proto-oncogene, which is 
related to the epithelial growth factor receptor (EGFR), is amplified in 10 to 
30 percent of infiltrating ductal carcinomas and 60 percent of ductal 
carcinoma in situ (DCIS) but is not amplified in benign breast disease[13]. 
Amplification of int-2, c-ras, c-myc, and cyclin D1 has also been found in 
breast cancer. Germ line mutations in p53 have been associated with 
breast cancer, and mutations in this tumor suppressor gene have also been 
found in spontaneous breast cancer. Somatic mutations in the 
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retinoblastoma tumor suppressor gene (Rb) have been found in breast 
cancer as well. [14-16] As mentioned, BRCA1 and BRCA2 have been shown 
to be involved in familial forms of breast cancer, yet somatic inactivation of 
these genes is at most extremely rare in spontaneous breast cancer[17-19b 
Stage of the disease — which involves tumor size, node status, and 
the presence of distant metastasis — is a better prognostic indicator than is 
histological subtype. Another factor in determining the prognosis is 
presence of the estrogen receptor (ER) and the progesterone receptor (PR) in 
the tumor cells. Loss of these receptors correlates with worse survival, 
partly because it indicates that growth of the tumor is not at all hormone 
mediated, and it precludes the effectiveness of endocrine therapies. The 
search for better markers of clinical outcome is ongoing. Growth fraction, 
aneuploidy, the presence of enzymes such as cathepsin B, and genetic 
alterations of oncogenes or tumor suppresser genes such as 
erbB-2/neu/HER-2 or p53 have been suggested, although they are not widely 
clinically utilized. [20] 
Part of the surgical intervention for breast cancer involves a 
dissection of the axillary lymph nodes. Procurement of the nodes in order 
to stage the disease is essential for prognosis and planning therapy, 
although it is possible that any therapeutic benefit may be replaced by a 
nonsurgical modality[21]. A prognostic marker as good or better than 
lymph node metastasis might replace the need for this procedure. The 
expression level of a protein related to metastasis could conceivably provide 
this necessary information. 
Beside looking for a better prognostic marker, there are other reasons 
why a better understanding of the alterations of protein expression in breast 
cancer may be clinically relevant. As benign changes can present either 
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clinically or radiographically similarly to early breast cancer, it is 
necessary to biopsy many lesions that turn out to be benign in order not to 
miss treatable breast cancers. In addition to being invasive, this is 
expensive. An alternative to open biopsy is fine needle aspiration for 
cytology. Inaccuracy of this technique precludes it from preventing a biopsy 
in many cases[22, 23]. Perhaps molecular analysis could increase the 
sensitivity of this test. 
Thymosin [515: 
Beta thymosins are a family of closely related, highly polar five 
kilodalton polypeptides. Thymosin (315, the newest addition to this family, 
was recently uncovered in a search for proteins with increased expression 
in motile as compared to poorly motile Dunning rat prostatic carcinoma 
cell lines. The protein, which is 5300 Da, was designated thymosin (315 
because of its approximately 60 percent homology with other members of 
the beta thymosin family. Human thymosin (315 was found to be identical 
in sequence to its rat counterpart. [24] 
The beta thymosins are thought to play an integral role in 
modulating the actin cytoskeleton. All vertebrates studied and some 
invertebrates are known to contain one or often two beta thymosins[25]. The 
precise role of any beta thymosin in regulating actin, however, is not well 
described, nor is the need for multiple beta thymosins or the potential 
differences in function between the members of this family fully 
appreciated. 
Thymosin (34 is the most abundant beta thymosin in most 
mammalian tissue and is the best studied member of this family. Current 
understanding is that thymosin (34 sequesters a large pool of monomeric 
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actin that is accessible to be released as needed for polymerization of actin 
filaments[261. In some cells, such as platelets[27[ and neutrophils[281, 
thymosin (34 can sequester the majority of actin monomers, while in other 
cells its level is only sufficient to sequester a smaller fraction of the 
unbound actin[29]. 
In vitro and in vivo experiments have demonstrated the role of 
thymosin [34 as a passive actin monomer sequestering protein, i.e. its 
function is mediated solely by altering the amount of available actin 
monomers — it is not directly involved in actin polymerization, nor does it 
otherwise affect the kinetics of that interaction[30]. As would be expected, 
microinjection or overexpression of thymosin [34 in cells has been shown to 
cause disassembly of actin stress fibers [31-33]. Similar results have been 
shown for other beta thymosins such as thymosin j310[33, 34], thymosin [39, 
and thymosin [3met9[35] confirming the role of the beta thymosins in 
sequestering actin monomers. Similarly, thymosin [315 was shown to bind 
monomeric actin and inhibit actin polymerization[24]. 
Recent data may dispute the notion that beta thymosins are simple 
actin monomer binding proteins, and the role of the beta thymosins with 
respect to actin may indeed be more complex. In contrast to previous 
studies where large excesses of beta thymosins in cells were shown to 
promote actin filament disassembly, a modest overexpression of thymosin 
[310 mediated by cDNA transfection in the NIH3T3 cell line paradoxically 
promoted actin filament assembly without changing the levels of other 
actin binding proteins. The actin filaments that were seen appeared 
thicker than normal and were clumped together. [29] 
A low affinity interaction between the filamentous form of actin and 
thymosin [34 has also been identified. When actin polymerizes in the setting 
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of a high concentration of thymosin (34, thymosin (34 is found to be 
associated with the actin filaments formed, which appear to self-associate 
and twist around each other. Also, whereas low concentrations of 
thymosin (34 cause a linear decrease in the amount of filamentous actin, 
under certain conditions the relationship plateaus at high concentrations of 
thymosin (34.[36] 
Regardless of their precise role, the interaction of the beta thymosins 
with the actin cytoskeleton suggests that they may be involved in important 
actin-mediated functions such as motility, cell differentiation, 
carcinogenesis, and metastasis. 
In many cells the actin cytoskeleton is a dynamic structure. In 
addition to helping provide architecture to the cell, as is well described in 
red blood cells[37, 38], it is now widely accepted that the constant 
remodeling of the actin network within the cell is important in driving cell 
locomotion. In fact, actin is necessary for cell movement in all but one of 
the animal cells studied, the exception being nematode sperm cells, in 
which another filamentous protein serves the role of actin[39]. 
Cell motility involves dramatic changes in the actin cytoskeleton 
mediated by rapid polymerization and depolymerization of actin filaments. 
The complex coordination required for cells to crawl or glide across a 
substrate has been well studied and much of what is known is beyond the 
scope of this text but is well reviewed elsewhere[39, 40]. In order for cell 
movement to proceed, spatial and temporal control of the simultaneous 
polymerization and depolymerization of filamentous actin, as well as 
similar maintenance of the monomeric actin pool is of paramount 
importance. 
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Control of actin polymerization and depolymerization is achieved by 
at least three mechanism: properties intrinsic to actin itself, the exchange 
of adenine nucleotides by actin monomers, and the interaction of actin with 
other proteins. The intrinsic polarity of actin filaments such that 
elongation is relatively favored at one end is an example of the first type of 
regulation. The fact that actin monomers bound to ATP are favored for 
polymerization and that actin monomers bound to ADP are released by 
filaments during depolymerization is an example of the second. The third 
type of control is accomplished by the wide array of proteins broadly 
classified under the term actin binding proteins or ABPs. The beta 
thymosins, of course, are examples of ABPs. [41] 
There are five major ways in which ABPs are thought to affect the 
dynamics of actin polymerization and depolymerization: 1) ABPs can cap 
the free ends of actin filaments to prevent elongation, 2) ABPs can suppress 
the nucleation of new actin filaments, 3) ABPs can sever actin filaments 
thus increasing the number of ends and hence facilitating 
depolymerization, 4) one ABP, profilin, directly participates in the addition 
of actin monomers to actin filaments thus promoting elongation, 5) ABPs 
such as the beta thymosins can buffer the concentration of free monomers 
such that elongation does not dramatically reduce the amount of available 
actin monomers. [41, 42] The participation of ABPs in the regulation of cell 
motility is reviewed elsewhere[30, 41, 42]. 
That actin should be involved in carcinogenesis and metastasis is 
logical. Motility is essential in the complex series of events that compose 
distant metastasis [43], Actin based motility may also be involved in the 
spread of a non-metastatic tumor within the tissue of origin. The actin 
cytoskeleton is known to have multiple physical linkages to membrane and 
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adhesion complexes[37, 38], some of which have well studied associations 
with neoplasia and metastasis. Direct evidence backing the crucial role of 
actin in the development of the neoplastic and metastatic phenotypes 
continues to mount. In many transformed or malignant cell types 
disturbances or alterations in actin itself or in the actin binding proteins 
has been demonstrated[43, 44]. 
The role of the beta thymosin family in cell motility is not well studied 
despite the ample evidence that the actin cytoskeleton is of paramount 
importance in mediating this function. In the studies where increased 
thymosin (310 expression ironically promoted actin filament assembly, it 
was shown that the increased expression of thymosin (310 also promoted 
cell spreading, chemotaxis, and the ability of the cells to heal a “wound” in 
a monolayer[29]. Thymosin (315 also appears to positively regulate cell 
motility as transfection of antisense thymosin (315 into motile rat prostatic 
carcinoma lines impairs cell motility in a Boyden chamber apparatus, 
while transfection of sense thymosin (315 increases the motility of poorly 
motile cell lines [24]. 
Given the properties of the beta thymosins with respect to the actin 
cytoskeleton, it would seem that they may be involved in cell differentiation, 
carcinogenesis, and metastasis. While this has been studied, the function 
of the beta thymosins in this respect is unclear. In some cell lines, 
increased thymosin (34 protein or mRNA has been shown to correlate with 
differentiation, while in others it has not[26]. Proliferating NIH3T3 cells 
have increased thymosin (34 mRNA levels compared to quiescent cells [45]. 
Thymosin (310 also appears to be related to the process of programmed cell 
death in that antisense thymosin (310 mRNA inhibits apoptosis mediated by 
A23187 and TNF-a[34], 
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In human tumors, thymosin (34 mRNA has been shown to be 
increased in hairy cell leukemia, while it is reduced in some 
lymphomas [46]. In one study, two out of three metastatic colorectal 
carcinomas showed decreased thymosin (34 mRNA compared to 
nonmetastatic tumors with the third metastatic tumor showing little 
change[47]. Thymosin (310 mRNA levels are increased in renal cell 
carcinomas[48, 49], and increased thymosin (310 expression was shown to 
correlate with the metastatic potential of melanomas[50]. 
As thymosin (315 has only recently been described, it is less well 
characterized. Its expression was shown to be increased in invasive human 
prostate cancers at both the mRNA and protein level as compared to the 
less invasive prostate cancers examined. Immunostaining of human 
prostate cancer cases also revealed a general correlation between Gleason 
grade — a measure of differentiation — and thymosin (315 expression, with 
high grade tumors (Gleason grade 8-10) showing increased staining 
compared to low grade tumors (Gleason grade 2-5). [24] 
The promising preliminary data from the prostate studies prompted 
us to undertake a study of thymosin (315 expression in human breast tissue. 
The aim was to determine the subcellular localization of thymosin (315 and 
whether thymosin (315 expression is associated with malignant changes of 
the breast epithelium. To do so, breast tissue representing a range of 
conditions from normal to neoplastic was examined using a polyclonal 
anti-thymosin (315 antibody. 

RESULTS: 
15 
Thymosin (315 is located diffusely throughout the cytoplasm but is excluded 
from the nucleus 
Paraffin-embedded tissue from both benign and malignant breast 
lesions was stained by the immunofluorescence method in order to 
determine the subcellular localization of thymosin (315 and the relative 
specificity of the affinity-purified anti-thymosin (315 antibody. In all breast 
epithelial cells, staining for thymosin (315 was located diffusely throughout 
the cytoplasm and was excluded from the nucleus (Figure 1). The intensity 
of the staining of breast epithelial cells varied from slide to slide and even 
within the same slide. While the intensity of the staining was not formally 
scored in the slides stained by the immunofluorescence method, it was 
clear that there was at least one example for both benign and malignant 
glands where there was intense staining, and at least one example for each 
of staining that was not significantly greater than background. The anti¬ 
thymosin (315 antibody stained endothelial cells in addition to the breast 
epithelial cells. Also, in some slides it seemed to stain more intensely in 
myoepithelial cells (Figure 1), but this finding was not represented in all 
the specimens. There was a minimal but noticeable background staining 
in the stromal elements throughout all the slides examined as compared to 
secondary antibody-only negative controls, which did not have any 
detectable signal. 
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Expression of thymosin (315 is increased in DCIS and invasive cancer 
compared with benign breast epithelium 
For ease of interpretation, the remainder of study was done using 
conventional peroxidase-based staining and standard light microscopy. 
Forty-three slides of surgical specimens obtained at Yale-New Haven 
Hospital, representing a spectrum of breast lesions, were stained using the 
anti-thymosin (315 antibody and visualized with a biotinylated secondary 
antibody, peroxidase-linked avidin and diaminobenzidine substrate. 
Twenty-one slides were from cases showing only benign changes, and 22 
slides had a primary diagnosis of malignancy (6 of these showed only 
ductal carcinoma in situ (DCIS) and 16 had infiltrating cancer). Many 
slides contained tissue representing more than one diagnosis, however, 
there were no malignant changes on any of the slides where the primary 
diagnosis was benign and no infiltrating cancer on slides from cases with 
the primary diagnosis of DCIS. All slides were from female patients, and 
the average age of the patients was 43 for the benign slides and 59 for the 
malignant slides. 
As with the immunofluorescent slides, there was some minimal 
background staining of the stroma. There were also variable levels of 
thymosin (315 expression in the epithelial elements. Each slide was 
examined and scored by three independent observers. Staining was scored 
on a scale from “0” (staining not greater than background) to “3+” (very 
intense staining). Examples of the different scores are shown in Figure 2. 
On each slide, normal glands, hyperplastic glands, DCIS, and 
infiltrating cancer were given separate scores based on the average 
intensity of staining of all the cells with the given diagnosis on the slide. A 
score for the average staining of all the benign elements on each slide was 
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also given. The three individual scores were compiled to give combined 
scores on a scale from zero to nine. Table 1 shows a summary of the benign 
cases including the diagnosis and overall score. Table 2 contains similar 
data for the malignant cases, but in addition to the overall score of the 
benign elements, it also includes scores for the DCIS and invasive cancer 
regions on each slide. For the slides with infiltrating cancer, the status of 
the axillary lymph nodes with respect to metastases, size of the resected 
tumor, estrogen receptor (ER) and progesterone receptor (PR) status, and 
ploidy of the tumor are shown. 
A summary of all the data separated by diagnosis is provided in Table 
3. The average score represents that for the combined elements for those 
slides with a benign primary diagnosis, that for the DCIS on the DCIS 
slides, and that for the infiltrating cancer on the slides with infiltrating 
cancer. The score for each slide could be converted to a binary value of 
either “positive” if it was greater than or equal to five, or “negative” if it was 
less than five. The percent of slides in each diagnosis scored as “positive” is 
also shown in Table 3. Distribution of the scores for the benign and 
malignant cases is shown in Figure 3, illustrating the preponderance of 
stronger staining in malignant epithelium than in benign epithelium. 
To evaluate these data for significance, a contingency table was 
constructed (Table 4). Calculation of the chi squared statistic shows a 
statistically significant increase in the number of malignant slides scored 
positive as compared with the benign slides (Fischer’s exact p-value = 
0.0002). There were also more DCIS slides scored as positive (p = 0.0149) 
and infiltrating cancer slides scored as positive (p = 0.0014) when these 
were compared individually to the benign slides. The slides of tumor with 
and without nodal metastasis were both more positive than the benign 
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slides when compared individually (p = 0.0329 and p =.0311 respectively). 
Among all the slides, nine cases could be selected that allowed the 
comparison between malignant cells and benign cells from the same 
patient on the same slide. In this group, the malignant cells were scored 
more positive than the adjacent benign cells (p = 0.0034). 
No correlation was found between staining pattern and age, node 
status, tumor size, ER status, PR status, or ploidy. 
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Thymosin [315, like other members of the beta thymosin family, is 
known to bind actin monomers and is thought to be associated with cell 
motility. Evidence that its expression is increased in human prostate 
cancers, and that this increase appears to correlate with grade of the 
disease suggests that it may mark metastatic potential[241. This study 
suggests breast tissue may show similar properties; that increased 
expression of thymosin [315 is associated with malignant changes of the 
ductal epithelium. 
Both ductal carcinoma in situ and infiltrating ductal carcinoma 
contain more thymosin (315 than benign breast tissue of several diagnoses 
such as fibroadenoma, sclerosing adenosis, and atypical hyperplasia. This 
increased expression can also be seen as significant when benign and 
malignant cells on the same slide are compared, neutralizing all 
confounding variables such as age that go along with the differences in the 
patient populations between the group with benign and the group with 
malignant breast disease. Thus increased expression seems to be more a 
feature of malignant changes as compared to benign changes in breast 
tissue. 
If indeed tumors progress from DCIS to nonmetastatic infiltrating 
ductal carcinoma to metastatic breast cancer, it seems that the increase in 
thymosin [315 expression can occur early in this process. Both DCIS and 
node negative breast cancer have increased thymosin [315 expression in this 
study indicating that upregulation of thymosin [315 may occur early in the 
oncogenic pathway. 
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This primary study is too small to assess an association between 
metastasis and expression of thymosin (315 in a meaningful way. 
Although, seven of eight tumors with nodal metastases at presentation 
showed positive staining, four of four node negative cancers scored and five 
of five in situ cancers scored were also positive. Thus while increased 
expression of this protein may be related to motility, in breast cancer it is 
not solely a feature of metastasis or even invasion. 
In the breast, thymosin (315 expression distinguishes malignant 
from benign lesions but possibly not metastatic from nonmetastatic tumors. 
This might be different from the prostate model, where thymosin (315 
expression was increased only in high grade and metastatic tumors. 
Perhaps the greater motility mediated by increased thymosin (315 is utilized 
by some intraepithelial and nonmetastatic breast cancers for spreading 
within ducts or within the breast, whereas in the prostate it is only needed 
for the ability to enter the blood vessels or lymphatics. 
While it now seems clear, at least in two tissues, that alterations in 
thymosin (315 expression occur with malignancy, it remains unclear 
whether this change is involved in driving the transformation or is instead 
a byproduct of the transformation itself. For instance, it is possible that 
increased thymosin (315 expression either causes increased cell motility 
through the sequestration of monomeric actin and hence the breakdown of 
actin stress fibers, or that it is merely a marker of the increased cell 
motility that the tumor has acquired through another mechanism. Other 
studies will be required to make this determination. 
In this study, levels of other ABPs or of other beta thymosins were not 
examined. Thus it is unclear whether the increased expression of 
thymosin (315 in breast cancer is unique or is common feature of related 

21 
proteins. It seems that the beta thymosins are independently regulated as, 
in the work with prostate, motility and malignancy were associated with 
increased thymosin (315 but not with variations in the expression of 
thymosin (34 or thymosin (310 in the cell lines or tissue samples studied[24]. 
It remains unknown whether this holds true for the breast. 
In any case, the increased thymosin (315 in breast and prostate 
malignancies gives more evidence to the logical assumption that the actin 
cytoskeleton plays an important role in carcinogenesis whether as a 
downstream effector of other changes or through “inside-out” signaling as 
an initiator of the process. 
In this study some malignant lesions stained weakly or moderately, 
while some of the benign tissue appeared to have a strong staining pattern. 
We are unsure of the significance of this observation. It is conceivable that 
there is a wide variation in thymosin (315 expression within a given lesion. 
While there are examples of benign tissue with increased expression and 
malignant tissue with baseline expression, overall malignancy trended 
toward increased thymosin (315 expression. Another explanation is that 
there is indeed a level of expression that is specific for malignancy, but this 
was hidden because the staining method employed here was not sensitive 
enough to always distinguish between small gradations in the level of 
protein within cells. 
Finally, it is possible that increased levels are associated with 
physiological epithelial remodeling, obscuring the changes associated with 
malignancy. As the breast is an organ that undergoes continual 
remodeling (associated with the menstrual cycle), it is not surprising to see 
this motility-related protein expressed in benign tissue. 
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The diagnostic utility of the increased thymosin (315 expression seen 
in malignancy remains to be determined. This work represents a pilot 
study, with insufficient numbers and follow-up to determine the 
independent prognostic value of this marker. Further work, including 
production of monoclonal antibody, providing for more specific staining and 
hopefully an increased ability to accurately quantitate expression, will be 
required for rigorous testing of these findings and determination of the 
value of this marker in prediction of metastasis. 
Within breast epithelium thymosin (315 is localized to the cytoplasmic 
compartment as is the case with thymosin [34 and thymosin (310(331. The 
cytoplasmic location of the beta thymosins is consistent with their 
association with the actin cytoskeleton. While myoepithelial cells may 
contain increased levels of thymosin (315 compared to breast epithelial cells, 
this seems to be an inconstant feature, and the significance of this is 
unclear. 
In summary, this study shows that thymosin (315 is contained within 
the cytoplasm of breast epithelial cells, and that thymosin (315 expression in 
increased in malignant as compared to benign breast tissue. Future 
studies are needed to determine the precise role and prognostic value of 
thymosin [315 in breast disease. 

The P120cas Study 
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INTRODUCTION: 
Colorectal Cancer 
Much like breast cancer, colorectal cancer is a problem of great 
magnitude. About 135,000 people will be diagnosed with colorectal cancer, 
and over 50,000 people will die from this disease in the United States this 
year. It is the second most common cause of cancer death next to lung 
cancer, and it is the second most common type of cancer in both women and 
men. Improved chemotherapy and screening has increased survival for 
those with colorectal cancer since the 1970s. [1] Similarly, increases in our 
surgical knowledge allowing for sphincter-sparing surgery have increased 
the quality of life for many with rectal cancer. Yet as the statistics indicate, 
the problem of colorectal cancer is still very much with us. 
The most significant risk factors of colorectal cancer are related to 
diet and a wide variety of predisposing conditions. Of the predisposing 
conditions there is inflammatory bowel disease and a host of hereditary 
conditions that result in kindreds with increased incidences of colorectal 
cancer[51]. In fact, up to about 10 percent of colorectal cancer probably 
arises in the setting of a familial predisposition[52]. The list of hereditary 
syndromes that can result in colorectal cancer is long and peppered with 
many eponyms. What bears mentioning is that most of these syndromes 
are characterized by polyposis, or the presence of multiple polyps in the 
large bowel.[51] It is in these adenomatous polyps that cancer arises. This 
is also the case with nonhereditary cases of colorectal cancer — the 
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majority of cases are thought to arise from pre-existing adenomatous 
polyps [53], 
The fact that colorectal cancer often arises from polyps is part of what 
makes this a useful model in which to study the progression of cancer. It is 
held that colorectal cancer progresses from benign epithelium through a 
series of histological changes including hyperproliferation of the 
epithelium, development of a polyp, increases in dysplasia, and the 
acquisition of villous or finger-like morphology. Conveniently, lesions at all 
stages of this progression — from small adenomatous polyps of low 
malignant potential to polyps with areas of severe dysplasia to cancers 
arising from and still contained within a polyp to large metastatic 
tumors — are accessible for study. [31 
As previously indicated, it appears that colorectal cancer progresses 
from a series of nonlethal genetic insults that accompany these histological 
changes. Benign polyps have alterations in tumor suppressor genes and 
oncogenes but in general not as many of these changes as full-blown 
cancers[3]. In specimens where cancer is seen with adjacent adenomatous 
changes, it can be shown that the cancer is genetically derived from the 
adenoma in that it has the same genetic changes but has at least one 
additional change as well[54, 551. 
APC, the gene mutated in the germ line of individuals with the 
familial adenomatous polyposis syndrome, is lost in 35 to 60 percent of 
sporadic colorectal tumors. This is the most common change in small, 
early adenomas. Mutations in the ras genes occur in about 50 percent of 
colorectal carcinomas and in a similar percentage of adenomas greater 
than 1 cm suggesting that this change most commonly occurs at the early 
adenoma stage. DCC, or the “deleted in colon cancer” gene, is located on 
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the chromosomal region 18q, which is lost in 70 percent of carcinomas and 
50 percent of late adenomas. The loss of 17p where p53 resides occurs in 75 
percent of colorectal cancer but is rarely found in adenomas suggesting 
that this change often occurs late in the transition from adenoma to 
carcinoma. [52] 
There are several potential clinical uses for molecular diagnostic 
techniques in colorectal cancer. First, mortality from this disease will be 
reduced by improved screening, which will allow detection of cancers and 
adenomatous polyps at earlier stages. Right now, the only noninvasive 
screening method widely used is the fecal occult blood test, which is 
notoriously lacking in both specificity and sensitivity[56]. While cancers 
can be directly visualized and polyps can be seen and removed by 
colonoscopy or sigmoidoscopy, limiting the widespread use of these 
procedures by first using noninvasive screening could lessen needless 
expense and discomfort. The best known marker for colorectal cancer is 
the blood level of the carcinoembryonic antigen (CEA), and although this 
has proved useful in screening for recurrence of colorectal cancer, it has 
not proven useful in screening for initial cases[57]. P53 mutations have 
been detected in the stool of some patients with colorectal cancer but this too 
has not yet proven useful for screening[58]. 
Another possible use for molecular diagnostic techniques is in 
increasing the use of sphincter-sparing surgery for rectal cancer. In colon 
cancer it is often possible to take a wide margin of resection and thus limit 
recurrence. In distal rectal cancer, however, it is often not possible to take 
such a margin without compromising the anal sphincter and thus 
necessitating a permanent colostomy. It is now generally accepted that a 
margin of 2 cm is satisfactory, and this has allowed continence to be 
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preserved for many patients[59-66]. Molecular assessment of surgical 
margins may allow for less than 2 cm to be taken in some cases thus 
affording a more comfortable survival for some patients. 
Lastly, as with all types of cancer, prognostic information is 
important both clinically and for the mental well-being of the patient. Right 
now the best information is provided by the depth of invasion of the tumor 
and the presence or absence of both lymph node and distant metastasis. 
Other histopathological data that can be used for prognosis includes the 
grade of the tumor, the presence of invasion into the pericolic fat, and the 
presence of invasion into lymphovascular structures.[51] A better 
understanding of the alterations in protein expression of colorectal 
carcinomas may allow for better prognosis, better assessment of surgical 
margins, or better screening. 
P120cas: 
A 120 kDa cadherin-associated src substrate, rather unglamoursly 
known as pl20cas, was discovered as a protein whose tyrosine 
phosphorylation in chicken cells expressing mutants of c-src tightly 
correlated with phenotypic transformation[67]. It was shown that pl20cas 
was also tyrosine phosphorylated when quiescent NIH3T3 cells were 
stimulated with growth factors such as epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), and colony-stimulating factor 1 
(CSF-1), thus placing this protein as a downstream effector of mitogen- 
induced signaling pathways [68]. Later research linked this protein both 
phylogenetically and physically with adhesion associated molecules. 
Though it was known to be membrane associated from its discovery, 
the first evidence linking pl20cas with cell adhesion came when cloning of 
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the gene identified 11 copies of a characteristic 42 amino acid repeat placing 
it in the arm family of proteins . The arm family — originally described for 
the Drosophila segment polarity gene product armadillo — is known to 
contain the catenins [3-catenin and plakoglobin (y-catenin).[69, 70] Later co¬ 
localization and immunoprecipitation experiments confirmed the 
hypothesis that pl20cas functions as part of the adhesion complex that 
contains the cadherins and the catenins[71, 72]. 
The cadherins are a superfamily of transmembrane glycoproteins 
that connect cells by calcium-dependent homotypic interactions between 
their extracellular domains. Within this superfamily is a subgroup called 
the classic cadherins — such as E-cadherin, N-cadherin and P-cadherin — 
that exist as groups of dimers on each cell and mediate the formation of 
adherens junctions (belt desmosomes) between cells. E-cadherin, the most 
prevalent cadherin in epithelial cells, is the best studied member of the 
group. Proper clustering and functioning of E-cadherin depends on 
interactions of its cytoplasmic domain. [73, 74] The catenins are a group of 
molecules that bind to the cytoplasmic tail of E-cadherin and are required 
for cell-cell adhesion[75, 76]. 
The catenins include [3-catenin, plakoglobin, a-catenin, and p!20cas. 
As mentioned [3-catenin and plakoglobin are two members of the arm 
family; they are 65 percent homologous with one another. They associate 
with the cytoplasmic region of E-cadherin in a mutually exclusive 
relationship. The proximity of the binding sites for (3-catenin and 
plakoglobin on E-cadherin probably prevents the binding of both proteins to 
a single molecule of E-cadherin, though it is possible for a dimer of E- 
cadherin to be bound to both proteins. The way in which E-cadherin selects 

28 
its binding partner is unknown, P120cas can also bind to the cytoplasmic 
tail of E-cadherin.[75] 
Either [3-catenin or plakoglobin can serve as a bridge between E- 
cadherin and a-catenin. Closely related to the actin binding protein 
vinculin, a-catenin is thought to link the complex to the actin cytoskeleton 
either by directly binding actin [77] or by binding a-actinin[78]. Both (3- 
catenin and plakoglobin bind a-catenin and link it to the cadherin complex, 
though a-catenin does not itself bind E-cadherin. P120cas does not bind 
directly to a-catenin. [79, 80] 
Defective interactions of any member of the cadherin complex result 
in failure of cell-cell adhesion. As will be seen, loss or defects in E- 
cadherin, a-catenin, [3-catenin, plakoglobin or pl20cas can result in loss of 
the epithelial phenotype. Tyrosine phosphorylation of [3-catenin, 
plakoglobin and p!20cas may also function in negative regulation of the 
complex and the loss of adhesive properties [81, 82]. 
Another interesting interaction of the catenins, especially in the 
colorectal cancer model, is that of [3-catenin and plakoglobin with the 
adenomatous polyposis coli gene product (APC). APC is a tumor 
suppressor gene discovered as the gene mutated in the familial syndrome 
characterized by the development of hundreds of neoplastic polyps in the 
colon, which if left unresected will inevitably develop a cancer at a very 
early age[83]. As previously mentioned, APC is also found to be mutated in 
a large percent of spontaneous colon cancers, and this change is considered 
one of the first steps in colon carcinogenesis [52]. 
Interestingly enough, APC is also known to have arm repeats, 
although its gene product localizes to the cytoplasm not the membrane[69]. 
Plakoglobin and [3-catenin bind to APC but cannot bind APC and E- 
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cadherin simultaneously. Although the significance of this is unknown, it 
is thought that APC downregulates (3-catenin and plakoglobin, and that the 
interaction between (3-catenin or plakoglobin and APC may be involved in 
contact inhibition of growth.[84] It has been shown that p!20cas does not 
interact with APC [80]. 
In the catenin family, [3-catenin and plakoglobin have no known 
alternative spliced forms whereas a second isoform has been identified for 
a-catenin[85]. P120cas, on the other hand, has several isoforms. Variation 
is seen between different types of cells in terms of isoform expression, and 
certain isoforms may correlate with differentiation[86]. The significance of 
this is still unknown. 
The idea that adhesion-related molecules should play an important 
role in carcinogenesis and metastasis is an old one. Pathologists have long 
observed that in carcinomas there is a loss of the normal epithelial 
morphology of the tissue of origin or a disorganization of cell-cell adhesion. 
This is especially prominent at the borders of a tumor where 
dedifferentiated cells are seen to infiltrate into the surrounding tissue[87, 
88]. The concept that down modulation of cell-cell adhesion molecules is 
responsible for mediating the increased mobility and invasiveness needed 
for the progression of carcinomas was proposed about 50 years ago[89-91]. 
For metastasis, it seems that downregulation of cell-cell adhesion 
molecules should be especially important. It is known that metastasis is a 
multi-step process involving loss of cell-cell adhesion, loss of cell-substrate 
adhesion, migration into the lymphatics or bloodstream, homing to a new 
site, and attachment to that new site. 
Cell adhesion molecules are now known to function in signal 
transduction, and thus in addition to mediating functions such as adhesion 
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and motility, they may be involved in other processes linked to 
carcinogenesis and metastasis such as growth, apoptosis, and gene 
expression. Furthermore, these molecules are involved in effecting 
differentiation by mediating such processes as compaction, transition from 
a mesenchymal to an epithelial morphology, and acquisition of normal 
tissue architecture — processes that seem to be reversed in cancer. [92] 
The cadherin complex is of paramount importance for cell-cell 
adhesion. All cell types that form solid tissues express cadherins . In 
general cells that express less cadherin complex molecules are less 
adhesive. Inactivation of other molecules of cell-cell adhesion has little 
effect on the cell so long as the cadherin complex is intact. The cadherin 
complex molecules are also generally associated with an epithelial versus a 
fibroblastic morphology. Furthermore, the cadherin complex is known to 
be associated with the gene products of several classic oncogenes such as 
src, yes and lyn.[74] 
For the above reasons, it is not unreasonable to think that the 
cadherin complex molecules would be involved in cancer. And in fact, it is 
known that alterations in E-cadherin, a-catenin, (3-catenin, plakoglobin or 
p!20cas can mediate the lack of adhesion and increased invasiveness or 
metastasis of many types of cell lines or tumors. As this is well described 
elsewhere[73, 93, 94], only those examples that relate to either pl20cas or 
colorectal cancer will be reviewed. 
While less well characterized than other members of the E-cadherin 
complex, alterations in pl20cas have been shown in cancer. As mentioned 
above, p!20cas was shown to have heterogeneous expression with isoform 
variation between cancer cell lines[86]. In a ras transformed human 
mammary cell line, tyrosine phosphorylation of p!20cas and [3-catenin was 
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noted to correspond with less developed adherens-type junctions between 
cells but increased focal adhesions. In these same cells increased pl20cas 
was detected on E-cadherin, but (3-catenin was notably absent from the 
complex[821. 
In a study involving human bladder cancers about one third of the 
tumors showed a heterogeneous staining pattern when examined with a 
monoclonal antibody that recognizes all known isoforms of pl20cas, with 
another six percent of the tumors showing total loss of pl20cas staining, 
and the remainder showing a staining pattern indistinguishable from 
normal urothelium. The pl20cas staining pattern in the bladder cancer 
study correlated with staining for E-cadherin, though interestingly there 
were a couple of cases in which there was complete loss E-cadherin 
expression with heterogeneous staining for pl20cas seen at the membrane 
begging the question of where the pl20cas was binding. The loss of staining 
for pl20cas also correlated with worse stage, grade and survival, although 
as far as survival is concerned the correlation between loss of pl20cas and 
poor survival was less strong than that seen for (3-catenin, a-catenin and E- 
cadherin.[95] 
In invasive ductal carcinoma of the breast, the breakdown was even 
with about one third of tumors showing each normal, heterogeneous, and 
complete loss staining patterns for pl20cas in one study. In a 40 X field 
selected as having the least staining, complete loss of pl20cas expression 
was seen in about two thirds of the same breast tumors. Paradoxically, loss 
or alteration of p!20cas was correlated with tumors that had not 
metastasized to the lymph nodes. [96] 
As is the case with other cancers, the cadherin complex molecules 
seem to play an important role in colorectal carcinoma. E-cadherin, [3- 
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catenin, oc-catenin and pl20cas have each been examined with regard to 
colorectal cancer using either cell lines or human tissue specimens. The 
data regarding each molecule’s part in colorectal carcinoma will be 
discussed separately below. 
E-cadherin’s relation to cell-cell adhesion, invasion, and metastasis 
has been extensively explored using colorectal cancer cell lines, and the 
data are all in concordance. Loss of E-cadherin in these cell lines 
correlates with invasion[97-100]. In those cell lines in which E-cadherin is 
expressed, monoclonal antibodies have been used to block that expression 
resulting in increased invasiveness [99] as well as inhibition of cell-cell 
adhesion and loss of glandular differentiation[101]. Transfection of E- 
cadherin into deficient cell lines resulted in increased cell-cell adhesion, 
increased epithelial morphology, decreased motility, decreased 
invasiveness and ability to form metastases in a host animal, decreased 
growth rate, and interestingly decreased secretion of a protease[97, 100]. 
Cell lines implanted in animals showed decreased E-cadherin expression 
compared to the same cell lines growing in vitro indicating that E-cadherin 
may be transiently regulated in colorectal cancer[98, 102]. 
Human pathological specimens have also been used to examine E- 
cadherin in colorectal cancer. Areas of architectural atypia in colorectal 
carcinoma were often found to have loss of E-cadherin staining[103, 104]. 
Membranous E-cadherin staining was also frequently found to be lost in 
adenomatous polyps that were greater than one centimeter, high grade, 
and with villous histology[104]. 
In general, metastatic foci of tumor had loss of E-cadherin 
expression[103, 104]. Interestingly, in some studies, many metastases that 
were found to have complete loss of E-cadherin originated from primary 
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tumors with strong E-cadherin staining[103, 104], however, one study found 
no striking differences in expression between lymphatic and hematogenous 
metastases compared with their primary tumors[105]. Surprisingly one 
paper reports that in tumors where cells could be visualized inside a 
vascular compartment, the intravascular component stained at least as 
intensely for E-cadherin compared to the extravascular component, and in 
no instance was there stronger E-cadherin expression in the tumor seen 
outside the vessel than was seen in the intravascular tumor cells[106]. 
E-cadherin expression has been shown to correlate inversely with 
grade[103, 104, 107]. One author reports that E-cadherin expression 
correlates with stage, such that low stage tumors — Dukes stage A and B 
(American Joint Committee on Cancer (AJCC) stage I and ID — have 
more E-cadherin expression than high stage tumors — Dukes stage C 
(AJCC stage III and IV)[103], Other studies could not find a correlation 
between E-cadherin expression and stage[104, 107], Loss of E-cadherin 
expression in colorectal carcinoma was reported to correlate with worse 
survival in one study[108]. 
Alterations of a-catenin expression in colorectal carcinomas have 
been detected as well. In one paper, three of five poorly differentiated 
colorectal cancer cell lines expressed E-cadherin, with two of these three 
actually having increased levels. These three cell lines were found to be 
deficient in a-catenin. Transfection of a-catenin into one of these deficient 
cell lines gave rise to cells that had increased calcium-dependent cell-cell 
adhesion and decreased migration on collagen compared to the parent 
cells.[109] 
Another paper examined deficiencies of the cadherin-catenin 
complex in relation to morphology and invasion. Of the colorectal cell lines 
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examined, those with an epithelial morphology were not invasive into 
embryonic chick hearts, while all but one with a round cell morphology 
were invasive. The cell lines with a round cell morphology were either 
deficient in E-cadherin or a-catenin. All the cell lines in this study 
expressed (3-catenin. Interestingly, all three cell lines that were deficient in 
a-catenin were derived from cell lines that originally had an epithelial 
morphology — one spontaneously emerged after several passages and two 
were created by transformation with the neo oncogene. [110] 
The finding that a-catenin expression is lost in some colorectal 
cancer cell lines carries over to human colorectal cancer specimens. 
Reduced a-catenin was seen in 80 percent of human colon cancers in one 
study with complete loss in 75 percent of the cases with reduced 
expression[lll]. In another paper, reduction of a-catenin expression 
seemed to correlate better with metastases to lymph nodes or to the liver 
than reduction of E-cadherin expression[112]. 
Only one study has examined [3-catenin’s role in colorectal 
carcinoma. In this paper, [3-catenin was found to have reduced expression 
in half of the colorectal cancers examined. In 71 percent of the cases, 
expression of E-cadherin correlated with the expression of [3-catenin, while 
in the remainder there was normal E-cadherin but reduced [3-catenin. 
Loss of [3-catenin also correlated with high grade tumors. [113] 
There is one paper in the literature that looked at pl2Qcas in 
colorectal cancer. In this series of 13 tumors, four had greater or equal to 
80 percent membrane staining of pl20cas (normal), six had between 10 to 80 
percent staining (heterogeneous), and three had less than 10 percent 
expression (complete loss). There seemed to be a general trend between 
pl20cas expression and E-cadherin expression, although there was not a 
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significant correlation. There was a correlation between loss of p!20cas 
and larger tumor size when the group of normal expressors was compared 
to the combined heterogeneous and complete loss groups. No correlation 
could be found with either distant metastasis or metastasis to the lymph 
nodes in this small group. [114] 
Given the ample evidence that alteration of the cadherin complex 
molecules is important in colorectal carcinogenesis and metastasis and the 
relative paucity of knowledge about the role of pl20cas in this model, it 
would seem reasonable to further explore the expression of pl20cas in 
human colorectal carcinomas. A larger study of pl20cas expression in 
human colorectal carcinoma than the one published would not only 
confirm the data already presented there, but could also possibly find 
clinicopathological correlations — such as with metastasis or survival — 
that the smaller study might have missed. Given the relation of loss of 
pl20cas expression with high grade, high stage, and decreased survival in 
bladder cancer as well as the paradoxical relationship between increased 
p!20cas expression and metastasis to lymph nodes in breast cancer, it 
would be reasonable to expect to find a correlation with alteration in p!20cas 
expression and these variables in colorectal cancer. 
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Many colon cancers show loss of pl20cas staining compared to normal 
colonic epithelium 
Paraffin-embedded slides from blocks selected to contain the junction 
between a colorectal cancer and benign epithelium were stained using a 
monoclonal antibody directed against pl20cas. For the pl20cas study, the 
immunofluorescence method was used throughout, as it was easier to 
quantify the level of expression when the clear membrane staining pattern 
of pl20cas could be appreciated. In the vast majority of slides, the tumor 
could be compared with an adjacent area of normal colonic epithelium that 
served as an internal control of pl20cas staining. The normal colonic 
epithelium uniformly stained strongly for p!20cas in a typical membranous 
pattern (Figure 4). In two slides there was no staining seen on the slide 
either in the tumor or in the control regions, and these were not scored. 
There were other slides in which only benign tissue was seen on the slide, 
and these also could not be included in the analysis. 
The expression of pl20cas in the tumors was quantifiable by the 
approximate percentage of cell membranes in which staining was seen. 
The 45 slides containing tumor were scored as described above. Briefly, 
both the overall staining of the tumor as seen on each slide and a 40 X field 
that represented the area of the tumor with the least staining were scored. 
The scoring system used was “+” for greater than 90 percent, for 
between 50 and 90 percent, “+/- for between 10 and 50 percent, and for 
less than 10 percent expression. Examples for each score are shown in 
Figure 5. The intensity of the staining is not reflected in the scoring system 
despite the fact that the tumors on the whole had less intense staining — 
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even when greater than 90 percent of the cell membranes stained — than 
the adjacent normal tissue (Figure 4). The scoring of the 45 slides and the 
clinicopathological data from each patient is shown in Tables 5 and 6. 
Interestingly, in one case two separate slides from the same patient 
were unintentionally stained and scored. In one section, the staining was 
scored as less than 10 percent, while in the other there was between 50 and 
90 percent pl20cas expression in the overall tumor as well as in the tumor 
area with the least staining seen on that slide. While it is impossible to say 
for sure, due to the large size of colorectal tumors, it is conceivable that one 
large area of the tumor had complete loss of pl20cas accounting for the 
absent expression seen in the one cut, while in another large area there 
was much less pronounced loss of pl20cas. The analysis was constructed 
as to be based on the reading of one slide for each tumor, despite the fact 
that colorectal tumors are much larger than one slide, and that an 
individual slide may not be representative of an entire tumor. For this 
reason, the two slides mentioned above were treated as if they were two 
separate cases with the same clinicopathological data. 
It is worth mentioning that an adenomatous polyps with variable 
pl20cas expression was incidentally appreciated on one of the slides not 
considered in this study because of the absence of any malignant histology. 
There seemed to be absent staining in areas of significant dysplasia (Figure 
4). The possibility that pl20cas may be lost in dysplastic polyps as well as in 
malignancy was not further studied. 
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Loss of greater than 50 percent of pl20cas staining correlates with larger 
tumor size compared with loss of less than 50 percent 
When the tumors were divided into two groups according to their 
overall expression of pl20cas by whether greater than or less than 50 
percent of the cell membranes stained, there was a significant difference in 
the size of the tumors between the two groups (p = 0.0120). The mean tumor 
size in the group with less than 50 percent pl20cas staining was 6.38 cm, 
and the mean in the group with greater than 50 percent staining was 4.24 
cm (Figure 6). 
Complete loss of pl20cas in a high power field representing the area of the 
tumor with the least staining correlates with metastasis 
Metastatic spread of colorectal primaries correlates with decreased 
expression of pl20cas. When the tumors were divided into two groups 
based on whether or not a 40 X field could be found in which there was 
complete loss of pl20cas — less than 10 percent of membrane staining — 
two significant correlations with metastasis could be appreciated. First, 
complete loss of pl20cas staining in a 40 X field correlates with AJCC stage 
III or IV disease, i.e. cancer that had metastasized to either the lymph 
nodes or a distant organ (p = 0.0470). The distribution of cases by stage for 
tumors with or without an area of complete loss of pl20cas expression can 
be seen in Figure 7. The tumors with an area of complete loss of pl20cas 
can be seen to have a higher proportion of advanced stage disease than is 
the case for the tumors without an area of complete loss. A contingency 
table constructed from these data is shown in Table 7. 
Not surprisingly, complete loss of pl20cas expression found in a 40 X 
field also correlates with lymph node metastasis alone (p - 0.0426). The 
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distribution of the “worst” scores for node negative and node positive tumors 
showing the high proportion of node positive cancers with an area of 
complete loss of pl20cas expression can be seen in Figure 8. The 
corresponding contingency table is also shown (Table 8). It bears 
mentioning that while the vast majority of tumors with an area of complete 
loss of pl20cas expression were metastatic by either of these two measures, 
the majority of metastatic tumors did not have a least staining region with 
complete loss of pl20cas expression. 
Loss of greater than 50 percent of pl20cas staining in a high power field 
correlates with the presence of histologically observed lymphovascular 
invasion 
Alteration of pl2Qcas expression also correlates with another sign of 
invasiveness. For each of the 45 slides, the absence or presence of invasion 
into a vascular or lymphatic structure was determined by reviewing the 
pathology report from each resection. In 19 tumors, such invasion was 
noted. Greater than 50 percent loss of pl20cas expression in the tumor area 
that stained the least correlates with the presence of histologically identified 
lymphovascular invasion (p = 0.0156). The distribution of “worst” scores 
separated by the presence or absence of lymphovascular invasion is shown 
in Figure 9. Most of the cases with lymphovascular invasion were scored 
as “+/- -” or “-” for their least staining area, whereas most of the cases 
without such invasion were given a “worst” score of The contingency 
table of these data can be seen as Table 9. 
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Greater than 50 percent loss of p!20cas staining in the tumor overall and 
complete loss of p!20cas in an area the size of a high power field both 
correlate with poor survival and shorter recurrence-free survival 
Patient follow-up data for each patient were obtained from the Yale- 
New Haven Tumor Registry. From this source, a date that the patient was 
last seen, as well as the status of the patient as either alive or dead could be 
used to generate a survival analysis. Loss of 50 percent of pl20cas 
expression on the entire portion of tumor seen on a single slide correlates 
with worse survival under this analysis (Mantel-Cox logrank p-value = 
0.0126). A Kaplan-Meier life table analysis of this association is shown in 
Figure 10. There was also a significant correlation between complete loss of 
pl20cas in the section of the slide that stained the least with poor survival 
(p - 0.0162). This also can be seen in Figure 10. 
Reviewing the Yale-New Haven Hospital pathology database, the 
presence or absence of pathologically documented tumor recurrence along 
with the date of the diagnosis could be determined if the diagnosis was 
made at this hospital. As seen in Table 6, four patients had such a 
recurrence representing five slides in this analysis. In all cases, the 
recurrence was metastatic as opposed to local. 
Two points on these data should be made. In one patient, the tumor 
that was scored was a local recurrence of a previous colorectal tumor. This 
patient is now alive and disease free. As it cannot be determined from these 
data whether the expression of pl20cas in the initial tumor would have been 
the same as in this recurrence, for the purpose of analysis this tumor was 
considered as if it were the first presentation of the disease. Thus this 
tumor is considered to have no recurrences, and both survival and disease- 
free survival are calculated from the date of the second operation. In 
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another patient, the colorectal tumor that was scored appeared about 20 
years after an operation for another colorectal cancer. As this is well 
beyond the time in which a local recurrence would be expected, this case is 
treated as a second primary. As seen in Table 6, this patient is also alive 
and disease free. 
The length of recurrence-free survival could be generated from the 
data mentioned above. As with overall survival, shorter recurrence-free 
survival correlates with loss of greater than 50 percent of pl20cas 
expression overall (p = 0.0313) and complete loss of pl20cas in an area the 
size of a high power field (p = 0.0369). The Kaplan-Meier life table analyses 
are shown in Figure 11. 
As loss of pl20cas expression correlates with advanced stage, and 
stage of colorectal cancer is a good prognostic indicator, it would seem that 
any correlation between loss of pl20cas and survival or recurrence-free 
survival would be based on the association between loss of pl20cas and 
stage. It should be noted that advanced stage — AJCC Stage III and IV 
disease — did not correlate with either worse survival or disease-free 
survival (p = 0.0644 and p = 0.0911 respectively), although as would be 
expected general trends were seen. Similarly correlations were not found 
between survival or recurrence-free survival and lymph node status (p = 
0.0549 and p = 0.0770), nor were they found between survival or recurrence- 
free survival and lymphovascular invasion (p = 0.5469 and p = 0.2361). The 
relatively small sample size precluded the assessment of the true 
independent predictive value of the overall or “worst” pl20cas expression. 
Other possible associations were examined but could not be found. 
The expression of pl20cas did not correlate with either patient age or 

42 
gender. Nor did it correlate with the location of the tumor within the large 
intestine (right colon, left colon, sigmoid or rectum). An association was 
similarly not found between p!20cas expression and tumor grade or 
between loss of p!20cas and mucinous or signet ring features as 
documented on the pathology report. P120cas expression was not found to 
correlate with the presence of a pathologically documented distant 
metastasis at the time of operation, the occurrence of a pathologically 
documented metastasis found in the follow-up period subsequent to the 
operation, or the occurrence of a pathologically documented distant 
metastasis found at either of these times. 
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P120cas is a member of the cell-cell adhesion complex that anchors 
epithelial cells together through the homotypic binding of E-cadherin. It is 
known that cells without this anchorage are usually more motile. In 
cancer, when the proteins of the cadherin complex are lost the result is a 
more metastatic phenotype[73]. This study shows that loss of pl20cas 
expression is a common feature in colorectal malignancy, and that cancers 
with pl20cas loss are more likely to be large, to be invasive, and to correlate 
with poor survival of the patient. 
In this study, tumors were scored for pl20cas expression in two 
ways. One score was based on the percent of cell membranes staining for 
p!20cas in the tumor seen on the entirety of one pathological slide. The 
other score was based on the percentage of cell membranes staining for 
pl20cas in an area of the tumor the size of a 40 X field selected as having the 
least expression. It should be noted that the correlation between loss of 
p!20cas expression and large tumor size was made using the “overall” 
score, while the associations between loss of pl20cas expression and more 
invasive tumors were made using the “worst” score. The correlations with 
outcome could be made using both scores. 
The data presented here confirm the results of a previous study 
showing that alteration of pl20cas expression is a frequent event in 
colorectal carcinoma[114]. Our study, however found a smaller percentage 
of tumors that had only 10 percent or less pl20cas staining (two out of 45 
slides or four percent versus three of 13 or 23 percent). The fraction of 
tumors with normal staining — greater than 90 percent in our study and 
greater than 80 percent in theirs — was roughly the same (12 of 45 or 27 
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percent versus four of 13 or 31 percent). The percentage scored as 
heterogeneous — between 90 and 10 percent staining in our study and 
between 80 and 10 percent in theirs — was close with the difference 
accounting for the smaller number scored for complete loss in our study (31 
of 45 slides or 69 percent versus six of 13 or 46 percent). 
Our data also confirm the result that loss of pl20cas expression 
correlates with large tumor size. As our results are drawn from a series of 
44 tumors compared to 13 in the previous study, additional weight is given 
to these findings. In our study, the correlation between tumor size and loss 
of pl20cas expression was made using the overall expression of pl20cas by 
comparing tumors with less than 50 percent expression against those with 
greater than 50 percent staining. 
The additional patients and the use of the “worst” scores allowed us to 
find correlations that the previous study could not. Our study found that 
loss of pl20cas expression is associated with invasion in three ways. 
Complete loss of pl20cas expression in a 40 X field correlates with both 
lymph node metastasis and higher stage (AJCC Stage III or IV). Loss of 
greater than 50 percent pl2Qcas expression in the area of the tumor with 
the least staining also correlates with invasion of the lymphovascular 
structures as seen histopathologically. 
The correlations with stage and nodal status are almost identical. 
The first analysis compares the group of tumors that had metastasized to 
the lymph nodes versus those that had not. The second analysis looks at 
AJCC Stage III tumors (those that are metastatic to lymph nodes but 
without distant metastasis) and Stage IV tumors (those that have distant 
metastases) compared to lower stage tumors. This switches the one tumor 
in our series with pathologically documented distant metastasis at the time 
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of operation but without positive lymph nodes (AJCC Stage IV but negative 
lymph nodes) from the “nonmetastatic” to the “metastatic” group. 
The third correlation compares a histopathological feature associated 
with metastatic behavior to pl20cas expression in the tumor area that 
stained the least. By scanning Table 5, it can be seen that the presence of 
lymphovascular invasion seems to be associated with actual metastasis, but 
that some of the metastatic tumors were not seen to be invasive into 
lymphovascular structures and similarly some tumors that were seen to 
invade into lymphovascular structures were not metastatic. A formal 
analysis would show the predicted result, lymphovascular invasion is 
significantly associated with AJCC Stage III and IV disease (p - 0.0023), 
lymph node invasion (p = 0.0013), the presence of pathologically documented 
distant metastasis at the time of operation (p = 0.0243), and the occurrence 
of a pathologically documented distant metastasis found either at the time 
of the operation or in the follow-up period (p = 0.0067). Thus the fact that 
loss of pl20cas expression correlates with lymphovascular invasion as seen 
histologically is further proof that loss of pl20cas is associated with 
metastasis and invasion in colorectal carcinomas. 
In this study the majority of metastatic tumors were not observed to 
have an area of complete loss of pl20cas. In all but one case, however, only 
one section was examined despite the large size of colorectal tumors. In the 
one case in which two slides were examined, which happened to be a case 
with metastatic disease, only one of the slides revealed an area with less 
than 10 percent expression of pl20cas. In order to more accurately 
comment on regional loss of pl20cas in a large tumor, multiple slides 
should be examined. If this were done, it may have revealed areas of loss in 
the metastatic tumors where none were found. It thus may be the case that 
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focal complete loss of pl20cas is essential for metastasis, or that there are 
other mechanisms equally capable of mediating metastatic behavior. 
If loss of p!20cas expression is seen as a marker for impaired 
function of the cadherin cell-cell adhesion complex in which p!20cas 
functions, then it is no surprise that such loss would correlate with 
metastasis in colorectal cancer. Metastasis in colorectal carcinomas was 
found to correlate with loss of other proteins involved the cadherin 
complex — E-cadherin in one study[103] and a-catenin[112] in another. 
Loss of pl20cas has also been shown to correlate with metastasis in bladder 
cancers[95], although interestingly it correlated inversely with metastasis 
in a study of breast cancers[96]. Our finding is consistent with the 
multitude of studies that have shown that loss of function of the E-cadherin 
complex causes decreased cell-cell adhesion as well as increased motility 
and invasiveness. Furthermore, this finding is in line with the hypothesis 
that loss of cadherin-mediated cell-cell adhesion can cause 
dedifferentiation or activation of oncogenic pathways and serves as 
additional evidence in its support. 
As the exact function of pl20cas within the E-cadherin complex is not 
understood, the significance of these findings cannot fully be appreciated. 
For instance, it is not known whether loss of p!20cas from the cadherin 
complex would be expected to directly cause loss of adhesion and 
metastasis. It may be that the loss of p!20cas seen in this study represents 
an underlying dysfunction of the cadherin complex and is not a primary 
event in causing the loss of adhesion. As E-cadherin expression was not 
analyzed in this study, it cannot be said with certainty that loss of pl20cas is 
not simply a marker for loss of E-cadherin at the membrane and hence loss 
of a site for p!20cas to bind. However, the bladder cancer study — which 
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found normal pl20cas expression at the membrane in some cases without 
any E-cadherin expression — indicates that loss of pl20cas and loss of E- 
cadherin, though associated, can be two distinct events [95]. Whether any of 
the changes in the cell-cell adhesion complex are primary events in 
achieving the metastatic phenotype or are downstream effects of other such 
changes is not known. It is also unclear why if loss of these molecules is 
associated with metastasis, they may be lost in highly dysplastic but benign 
polyps as is the case for E-cadherin[104] and may be the case for pl20cas. 
An explanation as to why metastasis should only correlate with loss 
of pl20cas expression as determined by the “worst” score, whereas tumor 
size only correlates with loss of pl20cas as determined by the “overall” score 
can be offered. Metastasis to the lymph nodes or elsewhere in the body is a 
complex process, but each metastatic depot could conceivably originate 
from one cell that detaches from the primary tumor. In other words if one 
of the many cells in a tumor is able to successfully complete the steps 
required in order for metastasis to succeed — including detachment from 
the primary tumor, invasion through the stroma, invasion into the 
lymphatics or blood stream, travel through the lymphatics or blood stream, 
migration from the lymphatics or blood stream, attachment to a distant 
site, and growth at the new site — then a metastatic tumor can form. Thus 
if only a small area loses function of the cell-cell adhesion complex, a cell 
from that one area may be able to metastasize. 
In contrast, in order for a tumor to grow to a large size, it may 
require the tumor to be composed of a dominant cell line with unregulated 
growth. As it is known that the E-cadherin complex is involved in signal 
transduction, it is conceivable that contacts with other cells may be 
transmitted into downregulation of growth through this complex. If it is 
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the case that function of the cell-cell adhesion complex in which pl20cas 
participates is required in the contact inhibition of growth, then loss of this 
function may promote uncontrolled growth. Thus loss of function of the 
cadherin cell-cell adhesion complex in large areas of the tumor may be 
associated with greater tumor size. 
The fact that loss of pl20cas expression should correlate with both 
survival and recurrence-free survival is consistent with the many of the 
functions of pl20cas and the cadherin cell-cell adhesion complex in which 
it participates. Survival should be based on numerous properties of the 
tumor including its capability to metastasize, its state of dedifferentiation, 
and its capacity for unregulated growth. What is interesting is that in this 
study survival and recurrence-free survival were significantly associated 
with loss of pl20cas expression but not with stage, lymph node metastasis, 
or lymphovascular invasion. Also, survival correlates with both the 
“overall” and the “worst” scores. 
The sample size and limited follow-up time in this study preclude 
any meaningful analysis of the independent predictive value of pl2Qcas 
expression on survival or disease-free survival. Nevertheless, the fact that 
p!20cas expression as quantitated by both the “overall” and “worst” scores is 
associated with survival and tumor-free survival more strongly than stage, 
lymph node metastasis, or lymphovascular invasion suggests that it may 
indeed have such independent predictive value. The predictive value of 
pl20cas expression on survival in relation to other cadherin complex 
proteins remains to be seen. In bladder cancer, it has been shown that 
expression of E-cadherin, a-catenin, and (3-catenin are better predictors of 
survival than is expression of p!20cas[951. 
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In summary, this study confirms the results of a much smaller 
study that loss of p!20cas expression is a common event in colorectal 
carcinoma and that such loss correlates with larger tumors. The current 
study furthers these results by showing that loss of p!20cas is related to 
metastasis in colorectal cancers, and that loss of pl20cas predicts a poor 
survival. Further studies will be needed to determine if loss of pl20cas is a 
cause of increased invasiveness or if it simply represents poor function of 
the cell-cell adhesion complex in which it functions. Additional studies 
will also be needed to determine whether loss of pl20cas is truly an 
independent predictor of poor survival and whether it is a better predictor 
than other cadherin complex molecules. Any possible clinical use of these 
data also awaits further study. 
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Patients and Tumor Specimens 
Thymosin [515 Study 
Forty-two formalin-fixed, paraffin-embedded tissue blocks were 
obtained from patients who underwent breast biopsies or breast resections 
between 1989 and 1996 at Yale-New Haven Hospital. Twenty-one blocks of 
breast biopsies that yielded a benign primary diagnosis as well an 
additional 21 blocks from resections or biopsies that yielded a malignant 
diagnosis of either ductal carcinoma in situ (DCIS), infiltrating ductal 
carcinoma, or infiltrating lobular carcinoma were selected. Blocks were 
selected by viewing the original pathological slides and obtaining the blocks 
from slides that had a large area of tissue representing the primary 
diagnosis of each case as well as adjacent areas of normal breast ducts and 
lobules to be used as control regions. 
P120cas Study 
Forty-four tissue blocks were similarly obtained for use in this study 
representing patients who underwent curative resections for colorectal 
cancer in 1993 and 1994 at Yale-New Haven Hospital. Blocks were selected 
for the original slides that showed the junction between the normal colonic 
epithelium and the tumor. 
Clinical information corresponding to the tissue blocks was obtained 
from the Yale-New Haven Hospital pathology database. For the pl20cas 
study, records from the Yale-New Haven Hospital Tumor Registry were 
also pulled to provide additional clinical information. This work was 
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performed under approval of the Yale Human Investigation Committee 
(HIC approval #8219) 
Antibodies 
Thymosin [515 Study 
An affinity-purified polyclonal antibody raised against the 11 C- 
terminal amino acids of thymosin (315 was used. The preparation and 
purification of this antibody has previously been described[24]. 
P120cas Study 
The pl20cas-specific monoclonal antibody 12F4 was chosen from a 
panel of pl20cas-specific monoclonal antibodies prepared previously[115] 
because of its excellent reactivity with formaldehyde-fixed tissue sections. 
This antibody binds to an epitope in the carboxy-terminal 121 amino acids of 
pl20cas and recognizes all known isoforms of pl20cas that can be 
distinguished by immunoprecipitation and western blotting analysis. The 
reagent used was affinity purified on protein A sepharose columns. 
The preparation of the antibodies was not performed by the principal author 
(J.S.G.). 
Immunohistochemical Analysis 
Standard histological sections were cut from the paraffin blocks, 
baked overnight at 60°C, and deparaffinized. Slides were then soaked in 
0.75 percent hydrogen peroxide in methanol to quench endogenous 
peroxidases. For antigen retrieval, each slide was immersed for five 
minutes in 6.5 mM sodium citrate, pH 6.0 in a heated conventional 
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pressure cooker[116]. Slides were blocked for one hour in 0.3 percent bovine 
serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO) diluted in Tris 
buffered saline (TBS), pH 8.0 (immunofluorescence) or normal serum from 
the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) diluted in 
TBS, pH 8.0 (immunoperoxidase). The slides were incubated for one hour 
with the appropriate primary antibody. Polyclonal anti-thymosin (315 
antibody was diluted 1:100 in the solution used for blocking, while the 
monoclonal antibody against pl20cas (12F4) was diluted 1:500. Slides were 
then washed seven times and incubated for one hour with secondary 
antibody. For the immunofluorescent specimens, Cy3-conjugated goat anti¬ 
rabbit IgG or Cy3-conjugated goat anti-mouse IgG (Jackson 
ImmunoResearch Labs, West Grove, PA) diluted 1:500 in TBS, pH 8.0 was 
used as the secondary antibody. Biotinylated goat-anti rabbit IgG diluted 
1:200 in TBS, pH 8.0 was used for the peroxidase-stained specimens. Slides 
were then washed seven times. The peroxidase-stained slides were 
incubated 30 minutes in the Vectastain ABC reagent (Vector Laboratories, 
Burlingame, CA) — which is composed of avidin and biotinylated 
horseradish peroxidase — prepared in TBS, pH 8.0 and then washed for 
five minutes in TBS, pH 8.0. All incubations were performed by coating the 
tissue with solution and storing the slides in a humidity chamber to prevent 
evaporation. The peroxidase-stained slides were further developed using 
the Vector DAB kit (Vector Laboratories, Burlingame, CA) — which 
employs diaminobenzidine and hydrogen peroxide — for six minutes. 
Peroxidase-stained slides were counterstained with hematoxylin. The 
immunofluorescent slides were coverslipped with N-propyl galate and 
sealed with nail polish, while the peroxidase-stained slides were 
coverslipped with Immu-mount (Shandon, Pittsburgh, PA). 
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Immunofluorescent slides were stored at -20°C to preserve the signal, while 
the peroxidase-stained slides could be stored at room temperature. 
Negative controls were prepared by substituting the primary antibody with • 
blocking solution in each protocol. 
Histological Scoring and Analysis 
Thymosin f315 Study 
Immunofluorescent slides were examined by two individuals (J.S.G., 
D.L.R.) on an Olympus AX-70 epifluorescence photomicroscope and 
representative photographs were obtained. For the peroxidase-stained 
specimens, each slide was examined by three observers (J.S.G., R.A.D.G., 
D.L.R.) using standard light microscopy. For each slide, each observer 
assigned up to five scores representative of different pathological elements 
contained on that slide. Each slide was scored for the staining of normal 
glands, hyperplastic glands, all benign cells, DCIS, and infiltrating cancer. 
The scores were based on the average staining of all the cells representing 
that diagnosis on the slide. Cells were scored as “0” if the staining was no 
greater than background, “1+” if staining was slightly greater than 
background, “2+” for an intermediate level of staining, and “3+” for very 
intense staining. If the observer deemed there to be insufficient or no tissue 
representing a particular diagnosis, a score was not assigned for that slide. 
Based on the scores from the three observers, a summary score was 
assigned for each element on each slide by totaling the scores if all three 
observers assigned scores, or if two observers assigned scores the sum was 
multiplied by 3/2 to bring the summary score to the correct scale. A 
summary score was not given if one or no observers scored a particular 
diagnosis on a slide. 
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P120cas Study 
All slides were examined by one individual (J.S.G.) on an Olympus 
AX-70 epifluorescence photomicroscope. The internal control regions of 
normal colonic epithelium were assessed for strong uniform staining. The 
tumors were compared to the control regions. The loss of pl20cas 
expression in the tumors was assessed by the same individual. The slides 
were scored as follows. 
A score was assigned for the expression of pl20cas both in the entire 
tumor seen on each slide and in a 40 X field that was chosen to represent 
the tumor area with the least staining on each slide. The latter “worst” 
score was used as it was hypothesized that regional loss of pl20cas might 
better predict metastasis than the overall level of expression. The percent of 
the cell membranes in which there was appreciable p!20cas staining was 
used as the basis of the scoring system. A score of “+” was given for greater 
than 90 percent staining, for between 50 and 90 percent, “+/- for 
between 10 and 50 percent, and for less than 10 percent. It should be 
noted that the percentage of the total cell membranes in which there was 
appreciable staining, regardless of intensity, was used for scoring purposes 
since the intensity of the signal would be more difficult to quantitate. 
Data analysis was accomplished using StatView 4.5 for Macintosh 
(Abacus Concepts, Berkeley, CA). 
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Figure 2. ** >k o •» 
Variation in the intensity of thymosin (315 expression in breast epithelial cells. Standard 
unstained histological sections were stained with an allinity-purilied polyclonal antibody 
directed against thymosin (315 and visualized with a peroxidase-based method. Panel A 
shows expression of thymosin [315 in benign breast ducts that is just greater than 
background. Panel B shows an intermediate expression level as seen in an infiltrating 
ductal carcinoma. A very intense staining pattern is seen in a different infiltrating ductal 
carcinoma (C). A scoring system was developed for the variation in thymosin [315 
expression in breast epithelial cells such that the staining was scored as either (A). 
“2+" (B), or '"3+’' (C). 
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Table 1. Summary of clinical data and thymosin pl5 staining of benign 
cases 
Primary 
Diagnosis 
Age Score 
fibroadenoma 36 6.0 
fibroadenoma 34 4.0 
fibroadenoma 24 4.0 
fibroadenoma 58 3.0 
fibroadenoma 18 7.0 
fibroadenoma 25 4.0 
fibroadenoma 37 2.0 
fibroadenoma 27 8.0 
fibroadenoma 60 3.0 
fibrocystic disease 40 3.0 
sclerosing adenosis 53 3.0 
sclerosing adenosis 56 6.0 
sclerosing adenosis 42 5.0 
sclerosing adenosis 43 3.0 
sclerosing adenosis 60 4.0 
atypical hyperplasia 54 7.0 
atypical hyperplasia 44 5.0 
atypical hyperplasia 29 • 
atypical hyperplasia 46 3.0 
atypical hyperplasia 57 4.0 
atypical hyperplasia 63 3.0 
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Table 3. Staining of slides for thymosin (315 grouped by diagnosis 
Primary Diagnosis Number 
of Slides 
Number 
Not Scored 
Average 
Score 
Percent 
Positive 
fibroadenoma 9 0 4.6 33 
fibrocystic disease 1 0 3.0 0 
sclerosing adenosis 5 0 4.2 40 
atypical hyperplasia 6 1 4.4 40 
all benign 21 1 4.3 35 
DCIS 6 1 6.2 100 
infiltrating ductal carcinoma 15 2 7.1 92 
infiltrating lobular carcinoma 1 1 • • 
all infiltrating cancer 16 3 7.1 92 
all malignant 22 4 6.9 94 
total 43 5 5.5 70 
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Figure 3. 
Distribution of cases by score of thymosin (3 15 staining in benign (A) and malignant (B) 
breast tissue. Forty-three slides of human breast tissue were stained with an affinity- 
purified polyclonal antibody to thymosin (315 and conventional peroxidase-based 
immunohistochemical methods. The slides were then scored by three observers for 
intensity of staining of the breast epithelium and the combined scores are shown grouped 
by benign (20 cases scored) or malignant (18 cases scored) primary diagnoses. Each bar 
on the histograms represents the number of cases with a score in a range including the 
number on the axis at its left margin and up to the number on the axis at its right margin. 
Each curve represents a normal distribution with the same mean and standard deviation as 
the scores on that histogram. The histograms show that the score of five seems to 
separate the benign from the malignant cases with the majority of benign cases scoring 
less than five, and all but one of the malignant cases scoring five or greater. 
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Table 4. Contingency table of benign or malignant slides versus “positive” or 
“negative” staining for thymosin (315 
Benign 
Malignant 
Totals 
Negative Positive Totals 
13 7 
1 17 
14 24 38 
y~ = 14.387, Fischer’s exact p-value = 0.0002 
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Table 5. Summary of histopathologic data and p!20cas staining of cases analyzed 
Number Tumor 
Location 
Tumor 
Size 
(in cm) 
Grade Stage Node 
Status 
Presence 
of Lympho- 
vascular 
Invasion 
Presence of 
Mucinous or 
Signet Ring 
Features 
Overall 
Score 
Worst 
Score 
1 right colon 5.0 2 I negative no no + /- + /- - 2 right colon 2.2 2 II negative no no + /- + /- 
3 right colon 4.5 3 III positive yes yes _ 
4 right colon 4.5 2 I negative no no + /- + /- 
5 right colon 4.0 2 II negative no no + + /- 6 right colon 4.0 2 IV positive no no + /- + /- 
7 right colon 4.5 2 II negative no no + /- + /-- 
8 right colon 5.0 2 II negative no no + + /- 
9 right colon 6.0 2 III positive no no + /- - _ 
10 right colon 2.5 2 III positive no no + + /- 
11 right colon 10.0 3 II negative no yes + /-- + /-- 
12 right colon 9.0 2 IV positive yes no + /-- _ 
13 right colon 5.0 3 IV positive yes no + /- - _ 
14 right colon 3.5 2 II negative no no + + /- 
15 right colon 3.2 2 I negative no no + /- 
16 rectum 4.0 2 rv positive yes no + /- - 
17 sigmoid 6.0 3 IV positive yes no + /- + /- 
18 right colon 3.8 2 hi positive yes no + /- + /- 
19 right colon 3.0 2 ii negative no no + /- + /- 
20 left colon 7.5 2 ii negative yes no + /-- + /- - 
21 right colon 2.0 3 IV positive yes no + /- + /-- 
22 rectum 3.5 2 III positive yes no + /- + /-- 
23 unknown 3.5 2 II negative no no + /- + /- 
24 left colon 5.0 2 III positive yes no + /- + /-- 
25 rectum 2.0 2 I negative no no + /- + /-- 
26 right colon 4.0 2 III positive no no + /-- - 
27 right colon 2.5 2 IV positive no no + + /- 
28 unknown 13.0 3 IV positive yes yes + + /-- 
29 right colon 3.5 2 II negative yes no + /- + /- - 
30 sigmoid 5.0 2 IV negative yes no + /- + /-- 
31 right colon 7.0 3 III positive yes yes + /- + /- 
32 rectum 4.0 2 II negative no no + /- + /- 
33 unknown unknown 3 III positive no no + + /- 
34 right colon 2.0 2 I negative no no + /- + /- 
35 sigmoid 3.0 2 II negative yes no + + /- 
36 right colon 4.5 2 II negative no no + + /- 
37 unknown 2.0 2 III positive no no + + /- 
38 sigmoid 4.0 2 III positive yes no + + /- - 
39 right colon 8.0 3 II negative no no + /- + /- 
40 left colon 5.0 2 II negative no no + /- + /-- 
41 right colon 6.0 2 II negative yes no + /- + /-- 
42§ left colon 4.0 2 III positive no no + /- + /-- 
43t left colon 3.0 2 II negative no no + + /- 
44* left colon 5.0 3 III positive yes yes - - 
45* left colon 5.0 3 III positive yes yes + /- + /- 
§ this patient had a bowel resection for colorectal cancer about 20 years before this tumor was diagnosed 
t this tumor is a recurrence of a colorectal cancer that was resected 439 days before this tumor was resected 
* these two slides are from the same tumor but were inadvertently both stained and scored separately 

Table 6. Summary of clinical data and p!20cas staining of cases analyzed 
Number Age Gender Alive 
or 
Dead 
Survival Presence of Recurrence- Overall Worst 
Days Subsequent Free Days Score Score 
Metastasis 
1 87 female alive 941 no 941 + /- + /- - 
2 73 female alive 742 no 742 + /- + /- 
3 67 male alive 762 no 762 
4 89 female alive 652 no 652 + /- + /- 
5 65 male alive 742 no 742 + + /- 
6 58 male alive 587 no 587 + /- + /- 
7 76 male alive 714 no 714 + /- + /-- 
8 85 female alive 611 no 611 + + /- 
9 87 male alive 755 no 755 + /- - 
10 64 female alive 737 no 737 + + /- 
11 83 female dead 487 no 487 + /- - + /- - 
12 88 male dead 574 no 574 + /- - 
13 61 female dead 200 no 200 + /- - 
14 87 female dead 582 no 582 + + /- 
15 62 female alive 28 no 28 + /- 
16 54 female alive 45 no 45 + /- . 
17 42 male dead 176 no 176 + /- + /- 
18 51 female alive 997 yes 997 + /- + /- 
19 70 female alive 699 no 699 + /- + /- 
20 74 female alive 881 no 881 + /- - + /- - 
21 55 female alive 904 no 904 + /- + /- - 
22 40 male alive 856 no 856 + /- + /- - 
23 55 male alive 321 no 321 + /- + /- 
24 71 male alive 797 no 797 + /- + /-- 
25 62 male alive 779 no 779 + /- + /- - 
26 84 female dead 566 no 566 + /-- _ 
27 63 female dead 449 no 449 + + /- 
28 88 female dead 74 no 74 + + /- - 
29 47 male alive 841 yes 519 + /- + /-- 
30 62 female alive 343 no 343 + /- + /-- 
31 70 male alive 1035 no 1035 + /- + /- 
32 66 male alive 1206 no 1206 + /- + /- 
33 62 female dead 539 no 539 + + /- 
34 67 male dead 583 yes 154 + /- + /- 
35 77 male alive 1231 no 1231 + + /- 
36 79 male alive 1003 no 1003 + + /- 
37 88 male alive 1325 no 1325 + + /- 
38 68 male alive 1213 no 1213 + + /- - 
39 81 female alive 1050 no 1050 + /- + /- 
40 62 male dead 1111 no 1111 + /- + /- - 
41 70 male alive 1150 no 1150 + /- + /- - 
42§ 81 female alive 845 no 845 + /- + /- - 
43t 61 female alive 1088 no 1088 + + /- 
44* 67 male dead 164 yes 58 - - 
45* 67 male dead 164 yes 58 + /- + /- 
§ this patient had a bowel resection for colorectal cancer about 20 years before this tumor was diagnosed 
t this tumor is a recurrence of a colorectal cancer that was resected 439 days before this tumor was resected 
* these two slides are from the same tumor but were inadvertently both stained and scored separately 
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> 50 percent < 50 percent 
Overall pl20cas Expression 
Figure 6. 
Tumor size for colorectal cancers with overall membrane expression of pl20cas greater 
than 50 percent versus those with expression less than 50 percent. Standard pathological 
sections from curative resections for colorectal cancer were stained with a monoclonal 
antibody directed at pl20cas and detected with an immunofluorescent secondary 
antibody. Slides were then assessed for pl20cas expression. Thirty-seven slides were 
scored as having greater than 50 percent of pl20cas expression overall and eight slides 
were scored for less than 50 percent expression. The tumor size was unknown for one 
case with greater than 50 percent staining. The histogram shows mean tumor size (+ 
standard error) for each group (unpaired t-test p-value = 0.0120). 
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Stage 
Stage 
Figure 7. 
Distribution of cases by stage for tumors with a least staining area showing retained 
pl20cas expression (A) or complete loss of pl20cas (B). Standard pathological sections 
from curative resections of colorectal tumors were stained with a monoclonal antibody 
directed at pl20cas and detected with an immunofluorescent secondary antibody. Slides 
were scored for percent of pl20cas expression overall and in a high power field that 
stained the least. The pathological stage at the time of the operation was determined from 
pathology records. Thirty-seven slides had a high power field with complete loss (less 
than 10 percent) pl20cas staining, and eight slides had some retained expression of 
pl20cas in the least staining areas. The distribution of stages for each group of cases is 
shown in the histograms above. It can be seen that most of the cases with greater than 50 
percent pl20cas expression are AJCC Stage I and II, whereas most of the cases with 
complete loss of staining are Stage III and IV. 
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Table 7. Contingency table of stage versus complete loss or expression of pl20cas 
the tumor area with the least staining 
Expression Complete Loss 
Low 21 1 
High 16 7 
Totals 37 8 
= 5.156, Fischer’s exact p-value = 0.0470 
Totals 
22 
23 
45 
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Worst Score 
+ /- + /-- 
Worst Score 
Figure 8. 
Distribution of “worst” scores of pl20cas expression by nodal status. Forty-five standard 
surgical pathological sections of colorectal cancers were stained with a monoclonal 
antibody directed at pl20cas and detected with an immunofluorescent secondary 
antibody. Slides were scored for percent of pl20cas expression overall and in a high 
power field selected for having the least staining. The presence or absence of metastasis 
to lymph nodes for each case was determined from pathology records. Twenty-three 
cases were node negative and 22 were node positive. The distribution of the assigned 
scores for pl20cas expression in the least staining areas is shown for node negative (A) 
and node positive (B) cases. The scores shown are “+/-” for between 50 and 90 percent 
membrane staining of pl20cas, “+/- for between 10 and 50 percent staining, and for 
less than 10 percent staining. It can be seen that most of the node negative cases have 
greater than 10 percent staining of pl20cas in the least staining area, whereas the node 
positive cases have a much more even distribution for amount of pl20cas expression. 
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Table 8. Contingency table of nodal status versus complete loss or expression of 
p!20cas in the tumor area with the least staining 
Expression Complete Loss Totals 
23 
22 
Totals 37 8 45 
X~ = 5.805, Fischer’s exact p-value = 0.0426 
Negative 
Positive 
22 1 
15 7 
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Worst Score 
Figure 9. 
Distribution of “worst” scores of pl20cas expression by absence (A) or presence (B) of 
lymphovascular invasion. Forty-five standard surgical pathological sections of colorectal 
cancers were stained with a monoclonal antibody directed at pl20cas and detected with 
an immunofluorescent secondary antibody. Slides were scored for percent of pl20cas 
expression overall and in a high power field selected for having the least staining. The 
presence or absence of histologically observed lymphovascular invasion was determined 
from the pathology reports. Twenty-six cases did not have lymphovascular invasion, 
while 19 did. The scores shown are “+/-” for between 50 and 90 percent membrane 
staining of pl20cas, “+/- -” for between 10 and 50 percent staining, and for less than 
10 percent staining. Most of the cases without lymphovascular invasion have greater 
than 10 percent staining of pl20cas in a least staining area, whereas the staining patterns 
of the cases with lymphovascular invasion are more evenly distributed. 
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Table 9. Contingency table of the presence or absence of lymphovascular invasion 
versus greater than or less than 50 percent pl20cas expression in the tumor area 
that stained the least 
> 50 percent < 50 percent 
Absent 17 9 
Present 5 14 
Totals 22 23 
Totals 
26 
19 
45 
yp- = 6.706, Fischer’s exact p-value = 0.0156 
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Days after Operation 
Days after Operation 
Figure 10. 
Kaplan-Meier Life Table Analysis of survival for patients with colorectal tumors having 
greater than or less than 50 percent pl20cas expression “overall” (A) and for patients 
having colorectal tumors with greater than or less than 10 percent pl20cas expression in 
the least staining area (B). Forty-five standard surgical pathology slides from patients 
having a resection of a colorectal cancer were stained with a monoclonal antibody 
specific for pl20cas and a Cy3-conjugated secondary antibody. The slides were scored 
for pl20cas expression overall and in a high power field selected for having the least 
staining. Follow-up data was collected from the Yale-New Haven Tumor Registry for 
each patient. Survival is significantly worse for the patients with less than 50 percent 
pl20cas expression overall than for those with greater than 50 percent pl20cas 
expression (p = 0.0126). Survival is also worse for the patients whose tumors had less 
than 10 percent expression of pl20cas in the least staining area compared to those with 
greater than 10 percent expression (p - 0.0162). 
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Figure 11. 
Kaplan-Meier Life Table Analysis of recurrence-free survival for patients with colorectal 
tumors having greater than or less than 50 percent pl20cas expression “overall” (A) and 
for tumors with greater than or less than 10 percent pl20cas expression in the least 
staining area (B). Forty-five standard surgical pathology slides from colorectal cancer 
resections were stained with a monoclonal antibody specific for pl20cas and detected 
with an immunofluorescent secondary antibody. The slides were scored for pl20cas 
expression overall and in a high power field selected for having the least staining. 
Follow-up data was collected from the Yale-New Haven Tumor Registry and the hospital 
pathology database. Disease-free survival is significantly worse for the patients with less 
than 50 percent pl20cas expression overall than for those with greater than 50 percent 
expression (p = 0.0313). Disease-free survival is also worse for the patients whose 
tumors have less than 10 percent expression of pl20cas in the least staining area 
compared to those with greater than 10 percent expression (p = 0.0369). 
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